2I9l2016
`
`GSK reaies 500 reps for Horizart laurch — FiercePhama
`
`<seIectanomersne I
`WSEESCIENC CAN
`SIGN ME UP
`
`REGENERON
`science to I779dIC/I76‘
`
`DO
`
`EMAIL ADDRESS
`
`Fierce-Pharma
`
`NEWS TOPICS ANALYSIS FEATURES LIBRARY EVENTS JOBS MARKETPLACE
`
`GSK readies 500 reps for Horizant launch
`April 8, 2011 |ByTracy Staton
`
`SHARE
`
`Email
`
`Now that they have FDA approval for Horizant in the bag, GIaxoSmithKIine and
`Xenoport are working out a sales strategy. And if the companies‘ statistics hold
`true, there are more than 5 million Americans with symptoms of restless legs
`syndrome, all potential buyers for this new treatment.
`
`There's been plenty of debate about whether restless legs constitute a "real"
`syndrome and whether sufferers really need a drug. To combat those arguments,
`Xenoport has data suggesting the syndrome doesn't just consist of its trademark
`leg twitchirg and restless sleep, but may be Inked to high blood pressure and
`heart disease. And the fact is, sufferers are seeking treatment
`
`That's where Horizant comes in, beginning July 1, the companies say.
`GIaxoSmithKIine will field a sales force of some 500 reps, Xenoport CEO Ron
`Barrett told FierceBiotech. Among their targets: The 60,000 to 70,000 primary care
`doctors and neurologists who now write most of the scrips for restless legs
`treatment
`
`.
`j:1.
`
`[webinar] Physician Prescribing Trends 8. opportunities for Health
`system-Pharma collaboration
`DATE WEDNESDAY, MARCH 16 | 11AM ETIBAM PT
`athenahealttr conducted a skrdyb learn how health systems and new reimbursement models
`are impacting prescribing behavior. We'll discuss our findings, including opporlrmities tor
`phamra marketers, witr a health system leader on our Marctr 16th wetrinar. Reserve Your Spot
`Today!
`
`Xenoport itself has the right to co-market the dnrg, brrt the company doesn't plan to
`do so right away, Barrett said. If it does decide to build up its own sales force, it
`would hire 50 to 100 reps to complement GSK's work. As Xconomy poirts out,
`Xenoport's share of profits varies according to how much it contrixutes to the
`partnershp with GSK.
`
`— read the Xconomy story
`— get more from the Los Angeles Times
`
`Related Articles:
`XenoPort rockets up after FDA approves Horizant for RLS
`
`litp1Iwww.lierceptamacorrrlstorylgsk-rearies-5(1)-repslu'izart-Iamchl201 1-04-08
`
`Page 1 of 2
`
`mowusI'§roa
`
`JOIN 150,000+ INSIDERS
`SIGN UP FOR OUR
`NEWSLETTER
`Fierr:ePlrarma is the phanna industnrs daily monitor,
`with a special locus on phamraceutical company
`news and the market development of FDA approved
`products. Join thousands of phanna industry leaders
`who get Fr'err:ePharma via daily email. Sign up today!
`vr rr‘r|r
`rrr
`rlr
`II
`III
`
`EMAIL ADDRESS
`
`SIGN ME UT‘
`
`THE STORY IN ACTION
`
`MAKING DRUGS
`
`L
`
`cs ALTHEA | THE POWER ill MAKE
`
`.4
`
`POPULAR STORIES
`
`MOST READ I MOST SHARED
`Doctors pounce on ‘alarmist,’ horrifying‘ Novarlis
`heart—faiIure ad
`
`Top exec exits as Pfizer redraws org chart for post-
`megamerger future
`NICE, in reversal, OKs Amgen's Repatha while
`snubbing Sanofi and Regeneron's Praluent
`Some top GSK investors aren't sold on a breakup-
`and they're backing CEO Witty, too
`PhRMA kicks off new ad campaign to doctor
`phanna's tarred image
`
`I THE LIBRARY: MULTIMEDIA
`FierceBiotech Radio on the burning hole in
`Gilead's $253 pocket and AbbVie's future in
`
`SENJU EXHIBIT 2307 1,3
`LUPIN V. SENJU
`
`IPR2015—01099
`
`

`

`21912016
`
`GSK reanies 500 reps for Haizarl launch — FiercePlama
`
`GSK, XenoPort revise Horizant pact
`
`h9mai°'09Y
`
` ‘W '°E°E‘°E" '°"°'5
`EMAIL ADDRESS
`SIGN MI: UP
`Fiemephannag caiy Hdfzui and
`Fien:eBiotecIr's Damian Gade
`tiscuss the discussion around Gilead
`Sciences‘ huge czh reserve and the many
`things the company might buy. Plus, a look
`
`| Filed under Glaxosnihltiie, Horizmt. Phuma odes reps. Restbss Leg Syndrome, Xenoport
`
`|
`
`coMMENTs
`spammed
`
`I HATE Annuities...and so Should You!
`
`If you have a $500,000 portfolio, uncover the truth about annuities
`by reading "Annuity Insights" from Forbes columnist Ken Fisher's
`flm.
`
`1 Comment
`
`FiercePharma
`
`. Recommend
`
`a shale
`
`Jom the dlscuss On‘ "
`
`%'L".§:...”“Z.°'£'?‘.‘.:’f’..;.,..""-’...."“‘...°'.....;.
`oertin biotech entrepreneur is bring'ng
`atteriion to an FDA loophole.
`
`"°RE "ms
`
`LATEST COMMENTARY
`
`Astraleneca chief chalks up milestones on his map
`to $458
`
`_
`0 Logln
`
`What's the cdendar bringing biopharma next year?
`_
`Our top 5 ideas
`
`son by Best _
`
`The most popular Fien:ePhanna stories of 2015
`Does new scnrtiny threaten pharma's specialty-
`phannacy strategy?
`
`Pfizer responds to FiercePhanna
`
`5 years ago
`Anonymous
`I can assure you RLS is a documented medical condition. I have had it since the age of
`12. As I age there have been times it has been so unbearable I have gone for weeks
`on an hour or two of sleep per night. When I was put on mirapex my sleep improved
`100%. The problem is, with time, mirapex becomes less efiective.
`
`R‘*P'V 3”“ '
`
`Dmcg Dfi;':;p1';_°:g '2'3:'('5°Eia;'e§&';:s°|
`(pflncegm may NJ _ spmsued By;
`Fiefliefliolech
`
`CBI's Global Anti-Corruption and FCPA
`Compliance Congress
`Mach 1517, 2016 — Philadelphia, PA
`
`ExI's 2nd Procurement and Outsourcing
`Summit
`Mach 22-23, 2016 — The Inn a Penn, A
`I-Elton Hotel — Philadelphia, PA
`MORE EVENTS
`
`'?'_u13EF.E"
`TIN‘
`TMFSIIIIVEY
`
`.
`
`CIJIIPLETE THE L.
`SIIIVEY Tlllllll
`
`PRESS RELEASES
`
`Immunovia announces collaboration with Mount Sinai Health System to
`validate early detection blood test for pancreatic cancer in a prospective
`clinical study
`First patient treated with LC Bead LUMl“' radiopaque embolic bead
`supported by Philips live image guidance
`Amplyx Phannaceuticals Expands Management Team and Increases Its
`Series B Financing to $49.2 Million
`SANOFI DELIVERED 2015 BUSINESS EPS UP 8.5% ON A REPORTED
`BASIS AND STABLE AT CONSTANT EXCHANGE RATES CONSISTENT
`WITH GUIDANCE
`
`CMS will cover percutaneous LAAC therapy for Medicare beneficiaries
`
`FEATURED JOBS
`
`> Need a job? Need to hire? Visit our jobs site.
`
`consistent with the FDA label when specific conditions are met
`
`Iitpjmwwfiercqiamacanlstaylgk-reaiesfitll-reps-Irxizan-Ian:N2[)11-04-(B
`
`2/3
`
`Page 2 of 2
`
`